AKT in cancer: new molecular insights and advances in drug development

by Mundi, Prabhjot S., Sachdev, Jasgit, McCourt, Carolyn, Kalinsky, Kevin
Published in Br J Clin Pharmacol (2016)

Does Race Affect Outcomes in Triple Negative Breast Cancer?

by Sachdev, Jasgit C., Ahmed, Saira, Mirza, Muhammad M., Farooq, Aamer, Kronish, Lori, Jahanzeb, Mohammad
Published 2010

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

by Beg, Muhammad S., Brenner, Andrew J., Sachdev, Jasgit, Borad, Mitesh, Kang, Yoon-Koo, Stoudemire, Jay, Smith, Susan, Bader, Andreas G., Kim, Sinil, Hong, David S.
Published in Invest New Drugs (2016)

TRLS-06. PHASE 1 EXPANSION STUDY OF IRINOTECAN LIPOSOME INJECTION (nal-IRI) IN PATIENTS WITH METASTATIC BREAST CANCER (mBC): FINDINGS FROM THE COHORT WITH ACTIVE BRAIN METASTASIS (...

by Anders, Carey, Munster, Pamela, Northfelt, Donald, Han, Hyo Sook, Ma, Cynthia, Maxwell, Fiona, Wang, Tiffany, Belanger, Bruce, Zhang, Bin, Moore, Yan, Sachdev, Jasgit C
Published in Neurooncol Adv (2019)

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase

by Sachdev, Jasgit C., Munster, Pamela, Northfelt, Donald W., Han, Hyo Sook, Ma, Cynthia, Maxwell, Fiona, Wang, Tiffany, Belanger, Bruce, Zhang, Bin, Moore, Yan, Thiagalingam, Arunthathi, Anders, Carey
Published in Breast Cancer Res Treat (2020)

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study

by Werner, Theresa L., Sachdev, Jasgit, Swisher, Elizabeth M., Gutierrez, Martin, Kittaneh, Muaiad, Stein, Mark N., Xiong, Hao, Dunbar, Martin, Sullivan, Danielle, Komarnitsky, Philip, McKee, Mark, Tan, Antoinette R.
Published in Cancer Med (2018)

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

by Mahalingam, Devalingam, Patel, Manish R., Sachdev, Jasgit C., Hart, Lowell L., Halama, Niels, Ramanathan, Ramesh K., Sarantopoulos, John, Völkel, Dirk, Youssef, Ashraf, de Jong, Floris A., Tsimberidou, Apostolia Maria
Published in Br J Clin Pharmacol (2020)

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

by Lin, Chia-Chi, Arkenau, Hendrik-Tobias, Lu, Sharon, Sachdev, Jasgit, de Castro Carpeño, Javier, Mita, Monica, Dziadziuszko, Rafal, Su, Wu-Chou, Bobilev, Dmitri, Hughes, Lorraine, Chan, Jian, Zhang, Zhi-Yi, Weiss, Glen J.
Published in Br J Cancer (2019)

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

by de Bono, Johann, Ramanathan, Ramesh K., Mina, Lida, Chugh, Rashmi, Glaspy, John, Rafii, Saeed, Kaye, Stan, Sachdev, Jasgit, Heymach, John, Smith, David C., Henshaw, Joshua W., Herriott, Ashleigh, Patterson, Miranda, Curtin, Nicola J., Byers, Lauren Averett, Wainberg, Zev A.
Published in Cancer Discov (2017)

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

by Hong, David S., Kang, Yoon-Koo, Borad, Mitesh, Sachdev, Jasgit, Ejadi, Samuel, Lim, Ho Yeong, Brenner, Andrew J., Park, Keunchil, Lee, Jae-Lyun, Kim, Tae-You, Shin, Sangjoon, Becerra, Carlos R., Falchook, Gerald, Stoudemire, Jay, Martin, Desiree, Kelnar, Kevin, Peltier, Heidi, Bonato, Vinicius, Bader, Andreas G., Smith, Susan, Kim, Sinil, O’Neill, Vincent, Beg, Muhammad S.
Published in Br J Cancer (2020)

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial

by Kalinsky, Kevin, Hong, Fangxin, McCourt, Carolyn K., Sachdev, Jasgit C., Mitchell, Edith P., Zwiebel, James A., Doyle, L. Austin, McShane, Lisa M., Li, Shuli, Gray, Robert J., Rubinstein, Larry V., Patton, David, Williams, Paul M., Hamilton, Stanley R., Conley, Barbara A., O’Dwyer, Peter J., Harris, Lyndsay N., Arteaga, Carlos L., Chen, Alice P., Flaherty, Keith T.
Published in JAMA Oncol (2020)

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

by Konstantinopoulos, Panagiotis A., Waggoner, Steven, Vidal, Gregory A., Mita, Monica, Moroney, John W., Holloway, Robert, Van Le, Linda, Sachdev, Jasgit C., Chapman-Davis, Eloise, Colon-Otero, Gerardo, Penson, Richard T., Matulonis, Ursula A., Kim, Young Bae, Moore, Kathleen N., Swisher, Elizabeth M., Färkkilä, Anniina, D’Andrea, Alan, Stringer-Reasor, Erica, Wang, Jing, Buerstatte, Nathan, Arora, Sujata, Graham, Julie R., Bobilev, Dmitri, Dezube, Bruce J., Munster, Pamela
Published in JAMA Oncol (2019)

Hepatobiliary Cancers: Clinical Practice Guidelines in Oncology™

by Benson, Al B., Abrams, Thomas A., Ben-Josef, Edgar, Bloomston, P. Mark, Botha, Jean F., Clary, Bryan M., Covey, Anne, Curley, Steven A., D'Angelica, Michael I., Davila, Rene, Ensminger, William D., Gibbs, John F., Laheru, Daniel, Malafa, Mokenge P., Marrero, Jorge, Meranze, Steven G., Mulvihill, Sean J., Park, James O., Posey, James A., Sachdev, Jasgit, Salem, Riad, Sigurdson, Elin R., Sofocleous, Constantinos, Vauthey, Jean-Nicolas, Venook, Alan P., Goff, Laura Williams, Yen, Yun, Zhu, Andrew X.
Published in J Natl Compr Canc Netw (2009)